Tanya Dorff (@tdorffonc) 's Twitter Profile
Tanya Dorff

@tdorffonc

medical oncology, genitourinary cancers

ID: 906606090393186304

calendar_today09-09-2017 19:51:50

1,1K Tweet

1,1K Followers

242 Following

Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

A terrific review on #ADCs in solid tumors led by Salvador Jaime-Casas, MD, working alongside Regina Barragan-Carrillo & mentored by Abhishek Tripathi City of Hope. Salvador is a super hard-working, thoughtful & brilliant med school graduate from #MexicoCity. He's on a roll in his 1st yr with us, being

A terrific review on #ADCs in solid tumors led by <a href="/SalvadorjcMD/">Salvador Jaime-Casas, MD</a>, working alongside <a href="/ReginaBarCar/">Regina Barragan-Carrillo</a> &amp; mentored by <a href="/AbhiTrip87/">Abhishek Tripathi</a> <a href="/cityofhope/">City of Hope</a>. Salvador is a super hard-working, thoughtful &amp; brilliant med school graduate from #MexicoCity. He's on a roll in his 1st yr with us, being
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

It keeps getting better at the #WorldGU24 World GU Conference 👉 Tanya Dorff provides solid argument for triplet over doublet in many patients with mHSPC #ProstateCancer and her conclusions👇SWOG Cancer Research Network trial on personalized addition of docetaxel in suboptimal PSA response at month 6 coming.

It keeps getting better at the #WorldGU24 <a href="/GUconference/">World GU Conference</a> 👉 <a href="/TDorffOnc/">Tanya Dorff</a> provides solid argument for triplet over doublet in many patients with mHSPC #ProstateCancer and her conclusions👇<a href="/SWOG/">SWOG Cancer Research Network</a> trial on personalized addition of docetaxel in suboptimal PSA response at month 6 coming.
Advanced Prostate Cancer Consensus Conference (@apccc_lugano) 's Twitter Profile Photo

"BRCA1, BRCA2 & Associated Cancer Risks and Management for Male Patients" Review discusses the underrecognized health implications of inherited cancer-predisposing variants in BRCA1🧬 and BRCA2🧬 (BRCA1/2 PVs) for male carriers, who comprise half of all carriers but are less

"BRCA1, BRCA2 &amp; Associated Cancer Risks and Management for Male Patients"

Review discusses the underrecognized health implications of inherited cancer-predisposing variants in BRCA1🧬 and BRCA2🧬 (BRCA1/2 PVs) for male carriers, who comprise half of all carriers but are less
Michael Harrison (@mrharrisonmd) 's Twitter Profile Photo

Brian Rini, MD pointing out that after ~20 years, we don’t fully know how to use TKIs in mRCC. Intermittent TKI used in real world practice. Provocative supporting data from STAR. Need data of iTKI in prospective obs. studies like ODYSSEY as well. Uromigos World GU Conference #WorldGU24

<a href="/brian_rini/">Brian Rini, MD</a> pointing out that after ~20 years, we don’t fully know how to use TKIs in mRCC. Intermittent TKI used in real world practice. Provocative supporting data from STAR. Need data of iTKI in prospective obs. studies like ODYSSEY as well. <a href="/Uromigos/">Uromigos</a> <a href="/GUconference/">World GU Conference</a> #WorldGU24
Tian Zhang, MD, MHS (@tiansterzhang) 's Twitter Profile Photo

Fiery discussion on minimal residual disease for #bladdercancer — ctDNA to replace radiology for disease recurrence? Tom Powles says emphatically yes. Brian Rini, MD says maybe complement radiology. We need to await Alliance for Clinical Trials in Oncology #MODERN trial from Matt Galsky Stephanie Berg !

Fiery discussion on minimal residual disease for #bladdercancer — ctDNA to replace radiology for disease recurrence? <a href="/tompowles1/">Tom Powles</a> says emphatically yes. <a href="/brian_rini/">Brian Rini, MD</a> says maybe complement radiology. We need to await <a href="/ALLIANCE_org/">Alliance for Clinical Trials in Oncology</a> #MODERN trial from <a href="/MattGalsky/">Matt Galsky</a> <a href="/bergsa83/">Stephanie Berg</a> !
Tanya Dorff (@tdorffonc) 's Twitter Profile Photo

Our 1st ⁦City of Hope⁩ GU program retreat was an unforgettable day of science and camaraderie. From immunotherapy to theranostics, microbiome to transcriptomics, we are ready to bring hope to all those with GU cancer as our program expands in CA, AZ, Chicago and Atlanta!

Our 1st ⁦<a href="/cityofhope/">City of Hope</a>⁩ GU program retreat was an unforgettable day of science and camaraderie. From immunotherapy to theranostics, microbiome to transcriptomics, we are ready to bring hope to all those with GU cancer as our program expands in CA, AZ, Chicago and Atlanta!
Prostate Cancer Foundation (@pcfnews) 's Twitter Profile Photo

Prostate cancer impacts Black men disproportionately vs. men of other backgrounds. Dr. John Carpten says lack of access to the right care is a key disparity Black men face. What are your thoughts? Watch the full recording here: bit.ly/3M5WKAE

Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Tall task given to Tycel Phillips, having to summarize EVERYTHING heme in 15 min at #CCCC24. From #talquetamab in MM (Dr. Amrita Krishnan in NEJM 2022) to #mosunetuzumab in FL (L. Elizabeth Budde, M.D., Ph.D. in The Lancet Oncology 2022) to #venetoclax in AML, he covered a wide range of topics

Tall task given to <a href="/LymphClinician/">Tycel Phillips</a>, having to summarize EVERYTHING heme in 15 min at #CCCC24. From #talquetamab in MM (<a href="/DoctorAKrishnan/">Dr. Amrita Krishnan</a> in <a href="/NEJM/">NEJM</a> 2022) to #mosunetuzumab in FL (<a href="/elizabeth_budde/">L. Elizabeth Budde, M.D., Ph.D.</a> in <a href="/TheLancetOncol/">The Lancet Oncology</a> 2022) to #venetoclax in AML, he covered a wide range of topics
Tom Powles (@tompowles1) 's Twitter Profile Photo

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important  than predefined  criteria <a href="/apolo_andrea/">Andrea Apolo, M.D.</a> <a href="/shilpaonc/">Shilpa Gupta</a> <a href="/OncoBellmunt/">joaquim bellmunt</a> <a href="/DrRosenbergMSK/">Jonathan Rosenberg MD</a> <a href="/MichvdHeijden/">Michiel van der Heijden</a> &amp; Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…
Ravi A Madan M.D. (@dr_ravimadan) 's Twitter Profile Photo

What if #immunotherapy 💉could impact #ProstateCancer as seen w/ #PSA 📉 & #PSMA🩻…but we’ve just been looking 👀 in the wrong place? Stop by @myesmo poster 🖼️ #1614 Sunday in the #ProstateCancer session #ESMO24

What if #immunotherapy 💉could impact #ProstateCancer as seen w/ #PSA 📉 &amp; #PSMA🩻…but we’ve just been looking 👀 in the wrong place?

Stop by @myesmo poster 🖼️ #1614 Sunday in the #ProstateCancer session #ESMO24
Tian Zhang, MD, MHS (@tiansterzhang) 's Twitter Profile Photo

Masterful discussion from Petros Grivas -- placing #NIAGARA in context of our #bladdercancer practice -- neoadjuvant and adjuvant OS benefits. Patients are living longer from earlier use of IO agents. Proposes future trial designs. ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors OncoAlert

Masterful discussion from <a href="/PGrivasMDPhD/">Petros Grivas</a> -- placing #NIAGARA in context of our #bladdercancer practice -- neoadjuvant and adjuvant OS benefits. Patients are living longer from earlier use of IO agents. Proposes future trial designs. <a href="/myESMO/">ESMO - Eur. Oncology</a> #ESMO24 #ESMOAmbassadors <a href="/OncoAlert/">OncoAlert</a>
Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

The honesty, thoughtfulness, and wit of Christopher Sweeney, MBBS Phase 3 trials of Immunotherapy in Prostate Cancer -- A Case Study of "Failed All-Comer Strategy" ⚡️8 negative trials 💰 >$700 million USD 👨‍🦰 7,305 patients #ESMO24 UroToday.com

The honesty, thoughtfulness, and wit of <a href="/ChrisSweens1/">Christopher Sweeney, MBBS</a> 

Phase 3 trials of Immunotherapy in Prostate Cancer -- 
A Case Study of "Failed All-Comer Strategy"

⚡️8 negative trials
💰 &gt;$700 million USD
👨‍🦰 7,305 patients

#ESMO24 <a href="/urotoday/">UroToday.com</a>
Jonathan Rosenberg MD (@drrosenbergmsk) 's Twitter Profile Photo

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years!  (Historical data &lt;5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024